Menopausal Disorders Drug Development Pipeline Review 2018

This report provides an overview of the pipeline landscape for menopausal disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for postmenopausal osteoporosis, vaginal atrophy and vasomotor symptoms of menopause, and features dormant and discontinued products.

Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone structure and body weight. There are 20 products in development for this indication.

Vaginal atrophy is thinning, drying and inflammation of the vaginal walls due to the body having less estrogen. Signs and symptoms include vaginal dryness, vaginal discharge, genital itching, burning with urination, and urgency with urination, urinary tract infections and urinary incontinence.

Request Sample Copy @https://www.premiummarketinsights.com/sample/GBI00004590

Risk factor includes smoking. Smoking impairs blood circulation, depriving the vagina and other tissues of oxygen. Tissue thinning occurs where blood flow is decreased or restricted. There are five products in development for this indication.

Vasomotor symptoms of menopause include hot flashes or night sweats that result from sudden opening of the blood vessels close to the skin, usually due to hormonal fluctuations in menopause and perimenopause. These symptoms are caused due to some medications, estrogen withdrawal, thyroid disease, diabetes, hyperhidrosis, anxiety and panic disorders, obesity, hormonally active tumors, chronic infections and neurological disorders. There are 12 products in development for this indication.

Molecular targets acted on by products in development for menopausal disorders include tumor necrosis factor ligand superfamily member 11, parathyroid hormone receptor and progesterone receptor. Companies operating in this pipeline space include Amgen, TherapeuticsMD and Ipsen.

Request for Discount @ https://www.premiummarketinsights.com/discount/GBI00004590

Companies Mentioned:

Amgen Inc

EndoCeutics Inc

Enteris BioPharma Inc

GL Pharm Tech Corp

Intas Pharmaceuticals Ltd

Ipsen SA

Ligand Pharmaceuticals Inc

Lupin Ltd

Luye Pharma Group Ltd

Medinova AG

Table of Contents:

1 Table of Contents

2 Introduction 7

3 Therapeutics Development 8

4 Therapeutics Assessment 18

5 Companies Involved in Therapeutics Development 35

6 Dormant Projects 46

7 Discontinued Products 49

8 Product Development Milestones 50

9 Appendix 83

Purchase Complete Report https://www.premiummarketinsights.com/buy/GBI00004590

Contact Info:
Name: Sameer Joshi
Email: [email protected]
Organization: Premium Market Insights
Phone: +1-646-491-9876

About Premium Market Insights:

Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider

Posted by on Monday May 20 2019, 6:34 AM EDT. All trademarks acknowledged. Filed under Business & Financial Services, Business Services, Diagnostics, Featured Press Release, Healthcare, Life Sciences, Pharmaceuticals. Comments and Trackbacks closed. Follow responses: RSS 2.0

Comments are closed

News Categories

Featured Press Releases

Latest News

Log in